CollPlant Biotechnologies (CLGN) Non-Current Deffered Revenue (2018)
CollPlant Biotechnologies (CLGN) posted Non-Current Deffered Revenue of $980000.0 for Q4 2018.
CollPlant Biotechnologies (CLGN) Non-Current Deffered Revenue (2018) Analysis & Trends
CollPlant Biotechnologies' Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $980000.0 for Q4 2018.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $980000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $980000.0 (changed N/A YoY) and the FY2018 annual result came in at $980000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue was $980000.0 for Q4 2018 at CollPlant Biotechnologies.
- Across five years, Non-Current Deffered Revenue topped out at $980000.0 in Q4 2018 and bottomed at $980000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | CollPlant Biotechnologies | 4.63 Mn | 4.63 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 980,000.00 |